Acorah Software Products - Accounts Production 19.3.600 false true false true No description of principal activity 12 November 2024 30 November 2025 30 November 2025 16075233 Mr D Smith iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 16075233 2024-11-11 16075233 2025-11-30 16075233 2024-11-12 2025-11-30 16075233 frs-core:CurrentFinancialInstruments 2025-11-30 16075233 frs-bus:PrivateLimitedCompanyLtd 2024-11-12 2025-11-30 16075233 frs-bus:FilletedAccounts 2024-11-12 2025-11-30 16075233 frs-bus:Micro-entities 2024-11-12 2025-11-30 16075233 frs-bus:AuditExempt-NoAccountantsReport 2024-11-12 2025-11-30 16075233 frs-bus:Director1 2024-11-12 2025-11-30
Registered number: 16075233
Resurgence Psychotherapy Ltd
Unaudited Financial Statements
For the Period 12 November 2024 to 30 November 2025
Balance Sheet
Registered number: 16075233
30 November 2025
£
Current assets 2,567
Creditors: Amounts Falling Due Within One Year (1,652 )
NET CURRENT ASSETS 915
TOTAL ASSETS LESS CURRENT LIABILITIES 915
Accruals and deferred income (680 )
NET ASSETS 235
CAPITAL AND RESERVES 235

Notes

1. General Information
Resurgence Psychotherapy Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 16075233 . The registered office is 21 Hill Street, Colne, BB8 0DH.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 2
2
For the period ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Mr D Smith
Director
05/08/2026